NASDAQ:INGN - Nasdaq - US45780L1044 - Common Stock - Currency: USD
9.52
-0.32 (-3.25%)
The current stock price of INGN is 9.52 USD. In the past month the price decreased by -17.07%. In the past year, price increased by 35.52%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 29.08 | 235.57B | ||
ISRG | INTUITIVE SURGICAL INC | 78.27 | 204.63B | ||
SYK | STRYKER CORP | 32.02 | 148.79B | ||
BSX | BOSTON SCIENTIFIC CORP | 40.13 | 148.44B | ||
MDT | MEDTRONIC PLC | 16.94 | 116.02B | ||
BDX | BECTON DICKINSON AND CO | 16.54 | 66.06B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.27 | 42.14B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.22 | 41.49B | ||
IDXX | IDEXX LABORATORIES INC | 40.88 | 37.65B | ||
RMD | RESMED INC | 26.72 | 34.69B | ||
DXCM | DEXCOM INC | 53.53 | 34.50B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 18.31 | 25.12B |
Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company is headquartered in Goleta, California and currently employs 834 full-time employees. The company went IPO on 2014-02-14. The firm supports patient respiratory care by developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. Its Inogen One systems reduces patients' reliance on stationary concentrators and oxygen compressed gas tanks. Its Inogen Connect is a wireless connectivity platform for the Inogen One G4, Inogen One G5 and Rove 6 consisting of a front-end mobile application for use by long-term oxygen therapy users and a back-end database portal for use by homecare providers. The company also offers Simeox, which is an airway clearance device.
INOGEN INC
859 Ward Drive
Goleta CALIFORNIA 93117 US
CEO: Nabil Shabshab
Employees: 834
Company Website: https://www.inogen.com/
Investor Relations: https://investor.inogen.com/
Phone: 18055620500
The current stock price of INGN is 9.52 USD. The price decreased by -3.25% in the last trading session.
The exchange symbol of INOGEN INC is INGN and it is listed on the Nasdaq exchange.
INGN stock is listed on the Nasdaq exchange.
9 analysts have analysed INGN and the average price target is 10.2 USD. This implies a price increase of 7.14% is expected in the next year compared to the current price of 9.52. Check the INOGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INOGEN INC (INGN) has a market capitalization of 227.53M USD. This makes INGN a Micro Cap stock.
INOGEN INC (INGN) currently has 834 employees.
INOGEN INC (INGN) has a support level at 9.19 and a resistance level at 10.1. Check the full technical report for a detailed analysis of INGN support and resistance levels.
The Revenue of INOGEN INC (INGN) is expected to grow by 4.55% in the next year. Check the estimates tab for more information on the INGN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
INGN does not pay a dividend.
INOGEN INC (INGN) will report earnings on 2025-05-05, after the market close.
INOGEN INC (INGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.52).
The outstanding short interest for INOGEN INC (INGN) is 3.41% of its float. Check the ownership tab for more information on the INGN short interest.
ChartMill assigns a technical rating of 2 / 10 to INGN. When comparing the yearly performance of all stocks, INGN is one of the better performing stocks in the market, outperforming 86.93% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to INGN. While INGN seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months INGN reported a non-GAAP Earnings per Share(EPS) of -1.52. The EPS increased by 49.16% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -17.21% | ||
ROE | -28.42% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 51% to INGN. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -0.66% and a revenue growth 4.55% for INGN